NCLT Chennai has sanctioned the amalgamation scheme of Orchid Pharma and Dhanuka Laboratories. The merger involves a share swap ratio of 161 Orchid Pharma shares for every 5 Dhanuka Laboratories shares, effective April 1, 2024. The NCLT viewed the scheme as not detrimental to shareholder interests.

Orchid Pharma and Dhanuka Laboratories Amalgamation Approved by NCLT

161 Orchid Pharma shares for every 5 Dhanuka Laboratories shares; Appointed Date April 01, 2024.

Reader Takeaway: NCLT approval for merger clears a major hurdle, but watch tax rights and charge discrepancies.

What just happened

The Chennai bench of the National Company Law Tribunal (NCLT) has sanctioned the Scheme of Amalgamation between Orchid Pharma Limited and Dhanuka Laboratories Limited. The appointed date for the amalgamation is April 01, 2024. The share swap ratio is set at 161 equity shares of Orchid Pharma for every 5 equity shares of Dhanuka Laboratories.

Why this matters

This NCLT sanction is a crucial step towards completing the merger. It is expected to create operational synergies, expand the product portfolio, and facilitate geographical reach for the combined entity. The management aims to streamline the group structure, reduce administrative costs, and leverage pooled resources.

The backstory

A resolution plan from May 16, 2019, had projected a potential sales turnover of ₹1,400 crore to ₹1,500 crore and EBITDA of ₹200 crore to ₹250 crore for the combined entity. The current sanction moves the company closer to realizing these historical targets.

What changes now

The approval allows the amalgamation process to proceed towards its legal 'Effective Date', which will be determined upon filing the certified NCLT order with the Registrar of Companies. The boards of both companies will mutually decide the record date for the share swap. Employees of Dhanuka Laboratories will be absorbed by Orchid Pharma without service interruption.

Risks to watch

Shareholders should be aware that the Income Tax Department reserves the right to initiate independent proceedings under the Income Tax Act, 1961. Additionally, the NCLT noted discrepancies between active charges in the Chartered Accountant's certificate and the MCA21 portal, which the companies must clarify.

Peer comparison

Industry consolidation through mergers and acquisitions is a common strategy for pharmaceutical companies in India to achieve scale, diversify portfolios, and enhance market competitiveness. Companies often look to combine operations to benefit from R&D synergies and reduce overlapping costs.

Context metrics

• Appointed Date: April 01, 2024
• Share Swap Ratio: 161 Orchid Pharma shares for 5 Dhanuka Laboratories shares

What to track next

Investors should monitor the official announcement of the 'Effective Date' of the merger, which follows the filing of the certified NCLT order. The mutual decision on the record date by both boards will also be key.